JonesTrading analyst Soumit Roy reiterated a Buy rating on Deciphera Pharmaceuticals (DCPH) today. The company’s shares closed last Monday at $49.99.
According to TipRanks.com, Roy is a 4-star analyst with an average return of 10.4% and a 30.0% success rate. Roy covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Monopar Therapeutics Inc, and Aeglea Biotherapeutics.
Deciphera Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $70.43, implying a 49.9% upside from current levels. In a report released yesterday, Nomura also maintained a Buy rating on the stock with a $84.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $71.11 and a one-year low of $19.88. Currently, Deciphera Pharmaceuticals has an average volume of 584K.
Based on the recent corporate insider activity of 40 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of DCPH in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Deciphera Pharmaceuticals, Inc. operates as a biotechnology company which develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. The company designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.
